Shots:

• The companies launch Nepexto- a biosimilar referencing Amgen's Enbrel- and is indicated for the mod. to sev. RA- JIA from the age of 2yrs.- active and progressive PsA- severe axSpA- mod. to sev. PsO and chronic severe PsO in children and adolescents from the age of 6yrs.
• Nepexto is available as a solution for injection in a pre-filled pen and prefilled syringe and has shown equivalent efficacy and safety to Enbrel
• The EC has approved MAA to Nepexto on Jun 04- 2020- following CHMP’s positive opinion. The approval underlines the scientific success of Mylan’s biologics program and expands Mylan’s therapeutic portfolio for immune-mediated diseases including RA

­ Ref: Lupin | Image: mAbxience